Cargando…

An Agreement Study Between Point-of-Care and Laboratory Activated Partial Thromboplastin Time for Anticoagulation Monitoring During Extracorporeal Membrane Oxygenation

BACKGROUND: Laboratory activated partial thromboplastin time (LAB-aPTT) is a widely used laboratory assay for monitoring unfractionated heparin (UFH) therapy during extracorporeal membrane oxygenation (ECMO). But LAB-aPTT is confined to a central laboratory, and the procedure is time-consuming. In c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teng, Yuan, Yan, Shujie, Liu, Gang, Lou, Song, Zhang, Yang, Ji, Bingyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276956/ https://www.ncbi.nlm.nih.gov/pubmed/35847800 http://dx.doi.org/10.3389/fmed.2022.931863

Ejemplares similares

A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy
por: Liu, Ying, et al.
Publicado: (2022)

An Ovine Model of Awake Veno-Arterial Extracorporeal Membrane Oxygenation
por: Qi, Jiachen, et al.
Publicado: (2021)

Anticoagulation on extracorporeal membrane oxygenation (ECMO)
por: Khilnani, Praveen
Publicado: (2017)

Exogenous Magnesium Chloride Reduces the Activated Partial Thromboplastin Times of Lupus Anticoagulant-Positive Patients
por: Tokutake, Takayoshi, et al.
Publicado: (2016)

Endogenous glycosaminoglycan anticoagulation in extracorporeal membrane oxygenation
por: MacLaren, Graeme, et al.
Publicado: (2014)

Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial
por: Aubron, Cécile, et al.
Publicado: (2023)

Monitoring anticoagulation during extracorporeal membrane oxygenation in patients with acute respiratory failure
por: Panigada, M, et al.
Publicado: (2013)

A Nationwide Three-Month Education Program for Venoarterial Extracorporeal Membrane Oxygenation
por: Gao, Sizhe, et al.
Publicado: (2023)

Anticoagulation in syncardia total artificial heart recipients: anti-factor Xa or activated partial thromboplastin time?
por: Monteagudo-Vela, María, et al.
Publicado: (2021)

Interrater agreement in classifying infections during extracorporeal membrane oxygenation
por: Verkerk, Karlijn, et al.
Publicado: (2023)

How to manage anticoagulation during extracorporeal membrane oxygenation
por: Levy, Jerrold H., et al.
Publicado: (2022)

Management of Anticoagulation during Extracorporeal Membrane Oxygenation in Children
por: Chegondi, Madhuradhar, et al.
Publicado: (2022)

Whole-blood Point-of-Care Activated Partial Thromboplastin Time Ratio (APR) is not Accurate Enough to Monitor Heparin Therapy in Patients with Severe Respiratory Failure Secondary to SARS-Cov-2 Infection Supported with Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)
por: Aston, Daniel, et al.
Publicado: (2022)

Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay
por: Billoir, Paul, et al.
Publicado: (2022)

An Unusual Etiology for Elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: Acquired Hemophilia and Lupus Anticoagulant
por: Seethala, Srikanth, et al.
Publicado: (2013)

The Effect of Sugammadex on Prothrombin and Activated Partial Thromboplastin Time
por: Samara, Evangelia, et al.
Publicado: (2021)

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
por: Han, Sang Jin, et al.
Publicado: (2011)

Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation
por: Burstein, Barry, et al.
Publicado: (2019)

Sodium alginate-hydrogel coatings on extracorporeal membrane oxygenation for anticoagulation
por: Gao, Wenqing, et al.
Publicado: (2022)

Effect of arterial oxygen partial pressure inflection point on Venoarterial extracorporeal membrane oxygenation for emergency cardiac support
por: Zhou, Hao, et al.
Publicado: (2021)

International normalized ratio and activated partial thromboplastin time testing
por: Chornenki, Nicholas L. J., et al.
Publicado: (2022)

Differences in the INR evaluation of two different thromboplastins in patients with positivity to lupus anticoagulant in ongoing oral anticoagulation
por: Ferrazzi, Paola, et al.
Publicado: (2010)

Anticoagulation Therapy during Extracorporeal Membrane Oxygenator Support in Pediatric Patients
por: Cho, Hwa Jin, et al.
Publicado: (2017)

Anticoagulation in COVID-19-positive Patients on Venovenous Extracorporeal Membrane Oxygenation
por: Patel, Mayuri, et al.
Publicado: (2022)

Context-Responsive Anticoagulation Reduces Complications in Pediatric Extracorporeal Membrane Oxygenation
por: Lin, John C., et al.
Publicado: (2021)

Anticoagulation Strategies during Extracorporeal Membrane Oxygenation: A Narrative Review
por: Rajsic, Sasa, et al.
Publicado: (2022)

Anticoagulation Management during Extracorporeal Membrane Oxygenation—A Mini-Review
por: Burša, Filip, et al.
Publicado: (2022)

Prevalence and Impact of Lupus Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation
por: Kornfehl, Andrea, et al.
Publicado: (2023)

Comparative analysis on characteristics of two activated partial thromboplastin time reagents
por: Yasui, Yutaro, et al.
Publicado: (2022)

Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk!
por: Santoro, Rita Carlotta, et al.
Publicado: (2023)

Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis
por: Kanouchi, Kazunori, et al.
Publicado: (2021)

The Problem of the Lipoid Thromboplastins
por: Milstone, J. H.
Publicado: (1950)

Lipoid Thromboplastin and Trypsin
por: Milstone, J. H., et al.
Publicado: (1954)

Hemodynamic evaluation and in vitro hemolysis evaluation of a novel centrifugal pump for extracorporeal membrane oxygenation
por: Fu, Minrui, et al.
Publicado: (2021)

Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation
por: Ranucci, Marco, et al.
Publicado: (2011)

COVID-19 necrotising pneumonia and extracorporeal membrane oxygenation: a challenge for anticoagulation
por: Goursaud, Suzanne, et al.
Publicado: (2020)

Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19
por: Seelhammer, Troy G., et al.
Publicado: (2021)

Anticoagulation Management in Severe Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation
por: Guo, Zhen, et al.
Publicado: (2021)

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2022)

Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms
por: Whitman-Purves, Emily, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_altfjp7sic9f1pjo58aj6tkdds